



8 June 2017

Motif Bio plc
("Motif Bio" or the "Company")

Notification of change in holding of significant shareholder

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 7 June 2017 by Aviva plc & its subsidiaries ("Aviva") that as at 6 June 2017 Aviva's direct interest in shares in the Company had changed. Aviva's total interest in the Company including its non-disclosable (indirect) position remains unchanged at 8,924,647 shares (4.5%). The full TR-1 disclosure is set out below.

For further information, please contact:

Motif Bio plc

Richard Morgan (Chairman)
Graham Lumsden (Chief Executive Officer)

info@motifbio.com

Peel Hunt LLP (NOMAD & BROKER)

Dr. Christopher Golden
Oliver Jackson

+ 44 (0)20 7418 8900

Northland Capital Partners Limited (BROKER)

Patrick Claridge/ David Hignell
John Howes/ Rob Rees (Broking)

+44 (0)203 861 6625

Walbrook PR Ltd. (FINANCIAL PR & IR)

Paul McManus
Mike Wort

+44 (0) 20 7933 8780 or motifbio@walbrookpr.com
Mob: +44 (0)7980 541 893
Mob: +44 (0)7900 608 002

MC Services AG (EUROPEAN IR)

Raimund Gabriel

+49 (0)89 210 2280

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ

Motif Bio plc

2. Reason for the notification (please tick the appropriate box or boxes):	
An acquisition or disposal of voting rights	√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached	√
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments	
An event changing the breakdown of voting rights	
Other (please specify):	
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	Aviva plc & its subsidiaries
4. Full name of shareholder(s) (if different from 3.): ^{iv}	Registered Holder: Available on Request 3,444* Chase (GA Group) Nominees Limited 3,354,076* HSBC Global Custody Nominee (UK) Limited 1,162,092* State Street Nominees Limited 103,780* *denotes direct interest
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	06 June 2017
6. Date on which issuer notified:	07 June 2017
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	>3% to <3% change at Direct Interest Level (Box 8A)

8. Notified details:		
A: Voting rights attached to shares ^{viii, ix}		
Class/type of shares	Situation previous to the triggering	Resulting situation after the triggering transaction

if possible using the ISIN CODE	transaction						
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights ^x	
			Direct	Direct ^{xi}	Indirect ^{xii}	Direct	Indirect
Ordinary Shares GB00BVVT4H71	6,895,922*	6,895,922*	4,623,392	4,623,392	** Not Disclosable	2.36%	** Not Disclosable

*Includes Right to Recall Loaned Shares (1,000,006)

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date ^{xiii}	Exercise/ Conversion Period ^{xiv}	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights
RIGHT TO RECALL LOANED SHARES	N/A	N/A	2,500,006* *Direct interest	1.27%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial instrument	Exercise price	Expiration date ^{xvii}	Exercise/ Conversion period ^{xviii}	Number of voting rights instrument refers to	% of voting rights ^{xix, xx}	
					Nominal	Delta

Total (A+B+C)

Number of voting rights	Percentage of voting rights
7,123,398	3.63%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^{xxi}

The voting rights are managed and controlled by **Aviva Investors Global Services Limited & Friends Provident International Limited**, with the following chain of controlled undertakings:-

Aviva Investors Global Services Limited:

- Aviva plc (Parent Company)
- Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)
- Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)
- Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Friends Provident International Limited:

- Aviva plc (Parent Company)
- Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)
- Friends Provident International Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

Proxy Voting:	
10. Name of the proxy holder:	See Section 4
11. Number of voting rights proxy holder will cease to hold:	
12. Date on which proxy holder will cease to hold voting rights:	

13. Additional information:	<p>Figures are based on the revised total number of voting rights of 196,212,108 as per the Company's Exercise of Warrants and Issue of Equity announcement of 2 May 2017.</p> <p>** Although not reportable, as per DTR5.1.5, the non-disclosable (indirect) position is currently 1,801,249 shares, and is included here in the interests of transparency.</p>
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	01603 684420